The impact of psychedelics on patients with alcohol use disorder: a systematic review with meta-analysis.
Current medical research and opinion February 1, 2024 Dakota Sicignano, Adrian V Hernandez, Benjamin Schiff et al. 19 citations
A meta-analysis of randomized controlled trials found that psychedelics, including LSD, increased the odds of patients with alcohol use disorder achieving abstinence or substantially reducing drinking compared to placebo. In double-blind, placebo-controlled trials, LSD (3 trials) produced an odds ratio of 1.99, and any psychedelic (4 trials) produced an odds ratio of 2.16. When including less rigorous controlled trials, the positive effect persisted. However, four of six trials had a high risk of bias and other methodological issues. One trial reported suicidal ideation and transient blood pressure increases, highlighting unresolved safety concerns. The evidence is promising but too weak for definitive conclusions; more rigorous trials are needed.